AveXis competitors

AveXis Competitors include Regenxbio, Lexicon Pharmaceuticals, Illumina and Oxford Genetics.
Add company...
AveXis
AveXis
AveXis is a biotech company developing innovative treatments for rare and life-threatening genetic diseases.
Regenxbio
Regenxbio
Regenxbio develops adeno-associated viral vector-based therapeutics and research tools, offering NAV, a recombinant AAV-vector.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.
Illumina
Illumina
Illumina is a global company that develops innovative array-based solutions for DNA, RNA, and protein analysis.
Oxford Genetics
Oxford Genetics
Oxford Genetics is a synthetic biology company, specializes in DNA design, protein expression optimization, and cell line development technologies and services.
Founding Date
Founding Date
2010
Founding Date
2009
Founding Date
1995
Founding Date
1998
Founding Date
2011
Type
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
Bannockburn, US HQ
Locations
Rockville, US HQ
Locations
Spring, US HQ
Jersey, JE
Washington, US
Tucson, US
The Woodlands, US
Tampa, US
Seattle, US
see more
Locations
San Diego, US HQ
Scoresby, AU
São Paulo, BR
Victoria, CA
Shanghai, CN
Beijing, CN
Minato, JP
see more
Locations
Oxford, GB HQ
Employees
Employees
N/A
Employees
10713% increase
Employees
1744% increase
Employees
6,200
Employees
542% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
2 b
Valuation ($)
788.1 m
Valuation ($)
49.1 b
Valuation ($)
N/A
Twitter followers
Twitter followers
505
Twitter followers
319
Twitter followers
108
Twitter followers
57 k
Twitter followers
665

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$10.4m (FY, 2017)
Revenue (est.)
$90.3m (FY, 2017)
Revenue (est.)
$2.8b (FY, 2017)
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$1.9m (FY, 2017)
Cost of goods
$926m (FY, 2017)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
$88.4m (FY, 2017)
Gross profit
$1.8b (FY, 2017)
Gross profit
N/A
Net income
Net income
($218.1m) (FY, 2017)
Net income
($73.2m) (FY, 2017)
Net income
N/A
Net income
$678m (FY, 2017)
Net income
N/A

Funding

Total funding raised
Total funding raised
$ 75m
Total funding raised
N/A
Total funding raised
$ 244.7m
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Regenxbio
HQ
Rockville, US
Employees
107↑ 13% increase

Regenxbio develops adeno-associated viral vector-based therapeutics and research tools, offering NAV, a recombinant AAV-vector.

View company
Lexicon Pharmaceuticals
HQ
Spring, US
Employees
174↑ 4% increase

Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.

View company
Illumina
HQ
San Diego, US
Employees
6,200

Illumina is a global company that develops innovative array-based solutions for DNA, RNA, and protein analysis.

View company
Oxford Genetics
HQ
Oxford, GB
Employees
54↓ 2% decrease

Oxford Genetics is a synthetic biology company, specializes in DNA design, protein expression optimization, and cell line development technologies and services.

View company